Dr. Lewis' research interests are focused on the development of new PET radiopharmaceuticals for the diagnosis and treatment of cancer. His work incorporates F-18, C-11, and nonstandard nuclide radiopharmaceutical development, with an emphasis on cancer detection and therapy, in both adults and children. The Lewis Lab works on the development of small molecules, radiolabeled peptides, antibodies and nanoparticles that target the overexpression of receptors and antigens on tumors as well as imaging changes in the tumor microenvironment associated with malignancy. One area of emphasis for the Lewis Lab has been centered around the remarkable specificity and selectivity of antibodies for cancer biomarkers have made immunoglobulins some of the most flexible and adaptable tools in modern medicine. For therapeutic purposes, a wide range of non-labeled antibodies has now entered the clinic. Antibody-based PET and SPECT imaging agents are not far behind. For example, an array of 89Zr-labeled radioimmunoconjugates has shown significant promise in both preclinical and clinical studies. Zirconium-89 has a number of distinct advantages which make it ideal for ImmunoPET including that the radioactive half-life of 78.4 h matches closely the extend times required for optimum biodistribution of intact mAbs. This Seaborg award presentation will review the current state-of-the-art on the use of radiometals with antibody constructs.

Award Address (Glenn T. Seaborg Award for Nuclear Chemistry sponsored by the ACS Division of Nuclear Chemistry and Technology). Jason S. Lewis, PhD

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.